Drug Trial Radar · NCT04084314
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
Last checked: Nov 20, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
701
Actual
Start
Sep 30, 2019
Primary completion
Feb 23, 2023
Study completion Mar 13, 2023
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 67 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 128-week open-label study to assess the long-term safety and tolerabilty of the monoclonal antibody erenumab in migraine patients.
Conditions
- Migraine
- Migraine Disorders
- Migraine Headache
Interventions
ErenumabBiological
Erenumab was supplied as a pre-filled pen (auto-injector) for subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Exposure Adjusted Incidence Rate of AE During Open-label Treatment Epoch Per 100 Subject YearsTime frame: Up to 128 weeks
Locations
75 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Alzenau in Unterfranken, Germany
Novartis Investigative Site
Bad Homburg, Germany
Novartis Investigative Site
Bad Honnef, Germany
Novartis Investigative Site
Bad Saarow, Germany
Novartis Investigative Site
Bayreuth, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Bielefeld, Germany
Novartis Investigative Site
Böblingen, Germany
Novartis Investigative Site
Bochum, Germany
Novartis Investigative Site
Bonn, Germany
Novartis Investigative Site
Bonn, Germany
Novartis Investigative Site
Chemnitz, Germany
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Dillingen, Germany
Novartis Investigative Site
Erbach im Odenwald, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
Freiburg im Breisgau, Germany
Novartis Investigative Site
Gelsenkirchen, Germany
Novartis Investigative Site
Greifswald, Germany
Novartis Investigative Site
Haar, Germany
Novartis Investigative Site
Halle, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Hoppegarten, Germany
Novartis Investigative Site
Ibbenbueren, Germany
Novartis Investigative Site
Jena, Germany
Novartis Investigative Site
Jülich, Germany
Novartis Investigative Site
Kassel, Germany
Novartis Investigative Site
Kiel, Germany
Novartis Investigative Site
Königstein im Taunus, Germany
Novartis Investigative Site
Leipzig, Germany
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.